checkmate 459: safety and efficacy of nivolumab versus sorafenib as a first-line treatment in ad...
Published 4 years ago • 120 plays • Length 6:21Download video MP4
Download video MP3
Similar videos
-
6:25
checkmate 459: long-term survival outcomes with nivolumab versus sorafenib as first-line treatme...
-
3:46
checkmate 459: updates on nivolumab monotherapy for hcc
-
8:38
checkmate 459: nivolumab plus chemotherapy for gc / gejc / eac
-
6:02
hcc: considerations in first-line use of sorafenib
-
4:59
adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with res...
-
2:58
arndt vogel, md, elaborates on the results of the checkmate-459 study in hcc
-
2:18
dr. welling on checkmate-040 trial of nivolumab in hcc
-
3:22
key takeaway 3: role of frontline i/o still pending
-
6:09
efficacy and early discontinuation predictors in nsclc patients receiving nivolumab
-
2:53
a patient with hepatocellular carcinoma (hcc) treated with nivolumab (opdivo) post sorafenib
-
2:01
updates from checkmate 040 in asian hcc patients
-
7:38
frontline clinical trials in liver cancer
-
14:19
new targets and new agents in hcc
-
1:42
sirt versus sorafenib in locally advanced hepatocellular carcinoma (sirvenib study)
-
5:06
phase 3 checkmate - 214
-
4:40
decision trial: support for sorafenib
-
4:58
long-term results from checkmate 040: nivolumab ipilimumab in advanced hcc
-
2:01
checkmate 172 trial of nivolumab for advanced melanoma: preliminary results
-
1:46
results from the celestial trial for patients with advanced hcc